Belatacept for kidney transplant recipients

  • Protocol
  • Intervention

Authors

  • Philip Masson,

    Corresponding author
    1. The University of Sydney, Sydney School of Public Health, Sydney, Australia
    Search for more papers by this author
  • Lorna Henderson,

    1. Royal Infirmary of Edinburgh, Department of Renal Medicine, Edinburgh, UK
    Search for more papers by this author
  • Jeremy R Chapman,

    1. Westmead Millennium Institute, The University of Sydney at Westmead, Centre for Transplant and Renal Research, Westmead, NSW, Australia
    Search for more papers by this author
  • Jonathan C Craig,

    1. The University of Sydney, Sydney School of Public Health, Sydney, Australia
    2. The Children's Hospital at Westmead, Cochrane Renal Group, Centre for Kidney Research, Westmead, NSW, Australia
    Search for more papers by this author
  • Angela C Webster

    1. The University of Sydney, Sydney School of Public Health, Sydney, Australia
    2. The Children's Hospital at Westmead, Cochrane Renal Group, Centre for Kidney Research, Westmead, NSW, Australia
    3. The University of Sydney at Westmead, Centre for Transplant and Renal Research, Westmead Millennium Institute, Westmead, NSW, Australia
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The objectives of this review are to:

  1. Compare the relative efficacy of belatacept versus any other immunosuppressive co-intervention for preventing acute rejection and maintaining kidney transplant function, and composite kidney transplant and recipient survival.

  2. Compare the incidence of several adverse events: Post-transplant lymphoproliferative disorder; other malignancies; IF/TA; infective complications; deterioration in blood pressure, lipid and glycaemic control.

  3. Assess any variation in effects by study, intervention and recipient characteristics, including: differences in pre-transplant Epstein-Barr virus status; belatacept dosing regimen; and donor-category (living, standard criteria deceased, or extended criteria deceased).

Ancillary